EUVIMEDSkopri EUVIMED
KohortenstudieOpen access · CC BY-NC-ND 4.0

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021

Mehdi Osooli iD, Siri Voghera, Gustaf Bruze, Caroline Nordenvall iD, SWIBREG Study Group, Hamed Khalili iD, Charlotte Hedin iD, Pär Myrelid iD, Åsa H Everhov iD, Jonas F Ludvigsson iD, Ola Olén

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70203 ↗

At a glance

Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Mehdi Osooli and 10 co-authors. Institution: Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Crohn Disease, Analgesics, Opioid, Drug Prescriptions. Cited 6 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Regional Agreement on Medical Training and Clinical Research between Stockholm County Council and Karolinska Institutet, Swedish Research Council, Karolinska Institutet Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Aims Population‐based data on prescribed opioid use among adults with Crohn's disease (CD) remain limited.

Methods

This nationwide register‐based study included individuals ≥ 18 years with incident (2008–2019) or prevalent (2008–2021) CD and up to 10 individually matched reference individuals without inflammatory bowel disease. We categorised opioid dispensations as weak (e.g., tramadol) or strong (e.g., oxycodone). We calculated the prevalence of ≥ 1 dispensation and mean daily doses (MDD) of opioids per 6 month period from 2 years before until 5 years following CD diagnosis (for incident cohort) and annual dispensation and MDD of opioids (for prevalent cohort).

Results

Among 10,527 patients with incident CD and 96,123 references, opioid dispensations were two‐fold among patients 2 years before diagnosis (26.2% vs. 12.6%) and remained high 13–36 months after diagnosis (26.5% vs. 11.7%). In the prevalent cohort (32,306 patients and 289,516 reference individuals), there was a declining trend in the use of dispensed opioids. During observation, the use of weak opioids decreased substantially among individuals with CD (16.0% vs. 6.0%) and reference individuals (8.0% vs. 3.0%). However, opioid MDD only decreased substantially among those with CD between 2008 and 2021.

Conclusion

Adults with incident CD had a two‐fold higher use of dispensed opioids than references 2 years before diagnosis, which peaked at three‐ and four‐fold higher use around diagnosis and remained high for 3–5 years. The decreased use of weak opioids might explain the recent decline in opioid consumption among patients with CD.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseAnalgesics, OpioidDrug PrescriptionsHumansAdultSwedenMaleFemaleMiddle AgedCohort StudiesYoung AdultRegistriesAgedPrevalenceAdolescent

Author keywords

Crohn's diseaseincidenceopioid usetime trend

Substances

Analgesics, Opioid

Authors and institutions

  • Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Pelvic Cancer, Unit of IBD-Surgery, Karolinska University Hospital, Stockholm, Sweden.
  • Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.

ORCID profiles: Mehdi Osooli, Caroline Nordenvall, Hamed Khalili, Charlotte Hedin, Pär Myrelid, Åsa H Everhov, Jonas F Ludvigsson

Funding

  • Regional Agreement on Medical Training and Clinical Research between Stockholm County Council and Karolinska Institutet
  • Swedish Research Council
  • Karolinska Institutet Foundation
  • Vetenskapsrådet

Cite

APA

Osooli, M., Voghera, S., Bruze, G., Nordenvall, C., SWIBREG Study Group, Khalili, H., Hedin, C., Myrelid, P., Everhov, Å. H., Ludvigsson, J. F., & Olén, O. (2025). Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70203

Vancouver

Osooli M, Voghera S, Bruze G, Nordenvall C, SWIBREG Study Group, Khalili H, et al. Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70203

BibTeX
@article{Osooli2025,
  author = {Osooli, Mehdi and Voghera, Siri and Bruze, Gustaf and Nordenvall, Caroline and SWIBREG Study Group, SWIBREG Study Group and Khalili, Hamed and Hedin, Charlotte and Myrelid, Pär and Everhov, Åsa H and Ludvigsson, Jonas F and Olén, Ola},
  title = {Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70203}
}
Start for free →